MAGEC2 is a cancer/testis antigen that functions as a regulator of protein degradation and tumor progression. Primary function: MAGEC2 enhances ubiquitin ligase activity of RING-type E3 ligases, particularly TRIM28, promoting p53 ubiquitination and degradation 1. However, MAGEC2 also stabilizes STAT3 by inhibiting its polyubiquitination and proteasomal degradation, leading to STAT3 accumulation in tumor cell nuclei 2. Additionally, MAGEC2 directly interacts with transcriptional coactivator TAF9 3. Mechanism: MAGEC2 acts through recruitment and stabilization of E2 conjugating enzymes at E3:substrate complexes, and its expression is upregulated by oncogenic MAPK/MEK pathway activation, where it suppresses p53 transactivation 4. Disease relevance: MAGEC2 is highly expressed in multiple cancer types including melanoma, hepatocellular carcinoma, and multiple myeloma but absent in normal somatic tissues except testis 1. MAGEC2 knockout reduces apoptosis resistance, cell proliferation, and migration while sensitizing cells to TNF-α-induced apoptosis 15. High MAGEC2 expression correlates with metastasis, unfavorable prognosis, and epithelial-mesenchymal transition 26. Clinical significance: MAGEC2 represents a tumor-specific immunotherapy target and independent prognostic factor for cancer survival 267. A genetic variant in MAGEC2 is associated with chondromalacia susceptibility 8.